Dr. Reddy's Laboratories Limited
DRREDDY.BO
Bombay Stock Exchange1,368.75
INR
-5.80
- -
Dr. Reddy's Laboratories Limited
DRREDDY.BO
(Bombay Stock Exchange)
Recent
price
1,368.75
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Dr. Reddy's Laboratories Limited (DRREDDY.BO), an Indian multinational pharmaceutical company founded in 1984 and headquartered in Hyderabad, India, with U.S. operations based in East Brunswick, New Jersey, develops, manufactures, and markets a broad portfolio of products and services across four main segments including generics (branded, unbranded, and biosimilars such as rituximab and bevacizumab), active pharmaceutical ingredients (APIs) and custom pharmaceutical services (including high-potency APIs, peptides, oncology products, and formulations like losartan potassium, telmisartan, and over 60 APIs), proprietary innovative medicines (such as toripalimab for nasopharyngeal carcinoma and lenacapavir for HIV-1), and consumer health solutions; the company produces over 190 medications targeting therapeutic areas including gastrointestinal, cardiovascular, diabetology, oncology, pain management, dermatology, critical care, and biotechnology, with key products encompassing abiraterone acetate, canagliflozin, ciprofloxacin hydrochloride, ramipril, terbinafine HCI, ibuprofen, sertraline hydrochloride, naproxen sodium, omeprazole, and diagnostic kits, serving markets in over 75 countries including the U.S., India, Russia, Europe, Latin America, Japan, and emerging regions through more than 25 active U.S. ANDAs, EU dossiers, and drug master files. Recent strategic developments include the September 2024 acquisition of Haleon's global nicotine replacement therapy (NRT) business (excluding the U.S.) for over Rs 5,000 crore, which has exceeded expectations and expanded its branded consumer health portfolio to approximately 45% of total sales; a June 2025 collaboration and license agreement with Alvotech to co-develop, manufacture, and commercialize a pembrolizumab (Keytruda) biosimilar candidate for global markets; a February 2025 licensing deal with Henlius for exclusive commercialization rights to the daratumumab biosimilar HLX15 (subcutaneous and intravenous formulations) in 43 countries including the U.S. and Europe, with up to $131.6 million in potential payments; launches of novel products such as the first UK-approved bevacizumab biosimilar, Skorolox (loxoprofen) in Russia, nirsevimab for RSV prevention in India, and a U.S. FDA-approved treatment for chronic idiopathic constipation; plans for 25-30 new product launches including six biosimilars by FY30 across key markets; and ongoing expansions in HIV treatments via partnership with Gilead, injectable contraceptives for low- and middle-income countries, and vaccine distribution in India.